
REPAY Board of Directors Authorizes Increase to Share Repurchase Program, Up to $75 million
ATLANTA--(BUSINESS WIRE)-- Repay Holdings Corporation (NASDAQ: RPAY) ('REPAY' or the 'Company'), a leading provider of integrated payment processing solutions, today announced that its Board of Directors has increased its authorized share repurchase program. The share repurchase program authorizes the Company to now purchase up to $75 million (up from $50 million) of the Company's Class A common stock. As of the date of this release, there remains approximately $61.2 million in capacity for share repurchases under the increased share repurchase program.
'This upsized buyback authorization reinforces the Board's confidence in REPAY's profitable growth and free cash flow generation,' said John Morris, CEO of REPAY. 'Our capital allocation priorities remain focused on maintaining a strong balance sheet and investing towards organic and inorganic opportunities to create value for shareholders. This increased authorization enhances our ability to make disciplined capital decisions based on REPAY's financial position and current market conditions.'
Repurchases under the program may be made in the open market, in privately negotiated transactions or otherwise, with the amount and timing of any repurchases depending on market conditions and corporate needs. Open market repurchases are expected to be structured to occur within the pricing and volume requirements of Rule 10b-18. The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of its shares under this authorization.
This program does not obligate the Company to acquire any particular amount of its Class A common stock and the program may be modified, suspended or discontinued at any time at the Company's discretion.
About REPAY
REPAY provides integrated payment processing solutions to verticals that have specific transaction processing needs. REPAY's proprietary, integrated payment technology platform reduces the complexity of electronic payments for clients, while enhancing the overall experience for consumers and businesses.
Forward-Looking Statements
This communication contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the share repurchase program, capital allocation initiatives, future financial and operating results, REPAY's plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as 'guidance,' 'will likely result,' 'are expected to,' 'will continue,' 'should,' 'is anticipated,' 'estimated,' 'believe,' 'intend,' 'plan,' 'projection,' 'outlook' or words of similar meaning. These forward-looking statements include, but are not limited to, statements regarding REPAY's growth and free cash flow generation and any share repurchases. Such forward-looking statements are based upon the current beliefs and expectations of REPAY's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond REPAY's control.
In addition to factors disclosed in REPAY's reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024, the following factors, among others, could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: exposure to economic conditions and political risk affecting the consumer loan market, the receivables management industry and consumer and commercial spending, including bank failures or other adverse events affecting financial institutions, inflationary pressures, evolving U.S. trade policies, general economic slowdown or recession; changes in the payment processing market in which REPAY competes, including with respect to its competitive landscape, technology evolution or regulatory changes; changes in the vertical markets that REPAY targets, including the regulatory environment applicable to REPAY's clients; the ability to retain, develop and hire key personnel; risks relating to REPAY's relationships within the payment ecosystem; risk that REPAY may not be able to execute its growth strategies, including identifying and executing acquisitions; risks relating to data security; changes in accounting policies applicable to REPAY; and the risk that REPAY may not be able to maintain effective internal controls.
Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance. All information set forth herein speaks only as of the date hereof in the case of information about REPAY or the date of such information in the case of information from persons other than REPAY, and REPAY disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication. Forecasts and estimates regarding REPAY's industry and end markets are based on sources it believes to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part. Pro forma, projected and estimated numbers are used for illustrative purpose only, are not forecasts and may not reflect actual results.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Lunda Construction Awarded $67.2 Million I-94 and I-394 Interchange Project in Minneapolis
BLACK RIVER FALLS, Wis., June 11, 2025--(BUSINESS WIRE)--Tutor Perini Corporation (NYSE: TPC) (the "Company"), a leading civil, building and specialty construction company, announced today that its subsidiary, Lunda Construction Company, has been awarded a contract by the Minnesota Department of Transportation valued at approximately $67.2 million for the I-94 and I-394 Interchange Project in Minneapolis. The scope of work includes repairing 34 bridges and ramps along I-394 and I-94 between downtown Minneapolis and Highway 100. The project also includes maintenance work on the Dunwoody Boulevard ramp, replacing the deck for the Penn Avenue bridge that crosses over I-394, and other improvements along I-394 between downtown Minneapolis and Highway 100. Work is expected to begin in July 2025 with substantial completion anticipated in the summer of 2027. The contract value has been added to the Company's backlog in the second quarter of 2025. About Tutor Perini Corporation Tutor Perini Corporation is a leading civil, building and specialty construction company offering diversified general contracting and design-build services to private customers and public agencies throughout the world. We have provided construction services since 1894 and have established a strong reputation within our markets by executing large, complex projects on time and within budget while adhering to strict safety and quality control measures. We offer general contracting, pre-construction planning and comprehensive project management services, and have strong expertise in delivering design-bid-build, design-build, construction management, and public-private partnership (P3) projects. We often self-perform multiple project components, including earthwork, excavation, concrete forming and placement, steel erection, electrical, mechanical, plumbing, heating, ventilation and air conditioning (HVAC), and fire protection. View source version on Contacts Tutor Perini CorporationJorge Casado, 818-362-8391Senior Vice President, Investor Relations and Corporate Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment's impending Phase 2 data for pulmonary arterial hypertension. A biopharmaceutical research team taking notes in front of a laboratory's microscope. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of the trial, of 20%, which is regarded as a definite success. If the results are encouraging, TPIP may replace Tyvaso, the current standard treatment. On June 4, Wells Fargo reaffirmed its Buy recommendation, with a price objective of $107. Shi points out that TPIP's once-daily dosage is a significant benefit over Tyvaso's four-times-daily schedule, which could increase adherence and make it more appealing to patients as well as physicians. The efficacy potential of TPIP is supported by interim study results that show additional advantages in six-minute walk distance (6MWD). Shi expects significant market penetration in light of these considerations, which could lead to an increase in Insmed Incorporated (NASDAQ:INSM)'s valuation. Both analysts highlight that if future trial results live up to predictions, TPIP has the potential to completely change the way that PAHs are treated. Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical firm that improves the lives of individuals suffering from serious and rare diseases. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S. Court of Appeals maintained the legality of its composition of matter patent for the medication Nuplazid, which treats psychosis in Parkinson's disease. A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments. The verdict supports ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in its legal struggle with India-based MSN Laboratories and upholds a December 2023 ruling by the U.S. District Court of Delaware. A later patent claim with the same priority date cannot be declared invalid by the court. According to CEO Catherine Owen Adams, Nuplazid's patent protection has been extended to 2030. The 34 mg capsule is also protected by a separate formulation patent that runs through 2038. The U.S. FDA authorized Nuplazid in 2016 to treat delusions and hallucinations linked to psychosis in Parkinson's disease. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)'s legal stance in a different action against Aurobindo Pharma was further strengthened by the latest decision. When taken as a whole, these results solidify the company's portfolio of intellectual property in the face of generic competition, guaranteeing prolonged market exclusivity for its flagship neurological medication. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical firm that specializes in the creation and marketing of medications that treat uncommon diseases and disorders of the central nervous system. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data